Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11840113 | 0.82 | SLC2A1 (0.42) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL5128327 | 0.80 | KDM4E (0.38) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL31044817 | 0.80 | FLT3 (0.54) | ADORA2AADORA1ADORA3KDM4EALDH1A1 | |
| SCHEMBL31045002 | 0.78 | MAPT (0.36) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL2307822 | 0.76 | ADORA2A (0.62) | ADORA2AADORA1 | |
| SCHEMBL31045057 | 0.76 | FLT3 (0.41) | ADORA3KDM4EALDH1A1 | |
| SCHEMBL20668057 | 0.76 | LMNA (0.50) | ADORA2AADORA1ADORA3KDM4EALDH1A1 | |
| SCHEMBL31044888 | 0.75 | KDM4E (0.33) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL31045332 | 0.75 | FLT3 (0.37) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL31045371 | 0.75 | FLT3 (0.55) | ADORA2AADORA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | ADORA2A 2408/4885ADORA1 3648/4885ADORA3 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.